Skip to main content

Table 3 Clinical outcomes of patients undergoing NGS and aCGH

From: Identification of mosaic and segmental aneuploidies by next-generation sequencing in preimplantation genetic screening can improve clinical outcomes compared to array-comparative genomic hybridization

  NGS aCGH P-value
Number of patients undergoing PGS 135 202
Number of embryos diagnose by PGSa 472 827
 Euploid 180 (38.1%) 364 (44.0%) 0.04*
 Aneuploid 219 (46.4%) 370 (44.7%) 0.60
 Mosaic 25 (5.3%) 14 (1.7%) <0.01**
 Segmental aneuploid 48 (10.2%) 79 (9.6%) 0.77
Number of patients with no euploid embryo to transfera 44 (32.6%) 42 (20.8%) 0.02*
 Aneuploid 23 (17.0%) 32 (15.8%) 0.77
 Mosaic 6 (4.4%) 0 (0%)
 Segmental aneuploid 15 (11.1%) 10 (5.0%) 0.05
Number of transferred patientsa 90 (66.7%) 129 (63.9%)
Mean female age (years)b 37.5 ± 5.5
(27–53)
37.2 ± 4.5
(27–51)
0.68
Indicationsa
 Severe male factor 9 (10%) 25 (19%) 0.08
 Advanced female age (≥36 years) 32 (36%) 42 (33%)
 Repeated implantation failure 32 (36%) 47 (36%)
 Oocyte –donation cycle for SET 17 (19%) 15 (12%)
Baseline AMH (ng/mL)b 4.5 ± 3.7 4.9 ± 3.6 0.42
Antral follicle countb 11.0 ± 4.6 11.2 ± 4.7 0.82
Mean endometrial thickness (mm)b 9.3 ± 1.8 9.2 ± 1.4 0.72
Clinical outcomes after the first cryotransfera
 HCG(+) pregnancy 66 (73%) 78 (60%) 0.048*
 Implantation 64 (53%) 67 (45%) 0.043*
 Clinical pregnancy 59 (66%) 73 (57%) 0.18
 Ongoing pregnancy 51 (57%) 59 (46%) 0.11
 Multiple pregnancy 3 (3%) 4 (3%) 1.00
 Miscarriage 8 (9%) 14 (11%) 0.48
Average transferred embryo per cryotransferb 1.2 ± 0.5 1.2 ± 0.4 0.11
  1. AMH anti-Müllerian hormone, NGS next-generation sequencing, aCGH array-comparative genomic hybridization, SET single embryo transfer
  2. *P-values <0.05 indicates statistical significance, and they are calculated by either the Mann-Whitney U test or Chi-square test depending on the population
  3. aData are presented as the number of the class (percentage of the class)
  4. bData are presented as mean ± SD